CONTEXT: Among the genomic loci harboring potential candidate genes for prostatic cancer (PCa) is the 2q31-33 chromosomal region that harbors the gene encoding phosphodiesterase 11A (PDE11A). In addition, the combined cancer genome expression metaanalysis datasets included PDE11A among the top 1% down-regulated genes in PCa. OBJECTIVE: In the present study, we screened 50 unrelated PCa patients of Brazilian descent for PDE11A coding defects. DESIGN: The study consisted of PDE11A sequencing, in vitro functional assays, and immunostaining analysis. RESULTS: We identified eight different sequence alterations in 15 patients (30%): one stop-codon and seven missense mutations. Three of the variants (R202C, Y658C, and E840K) were novel, and the remaining five (Y727C, R804H, R867G, M878V, and R307X) have been associated with predisposition to adrenal or testicular tumors. The overall prevalence of PDE11A-inactivating sequence variants among PCa patients was significantly higher than in 287 healthy controls (0.16 vs. 0.051, respectively, P < 0.001, odds ratio 3.81, 95% confidence interval 1.86-7.81) and the R202C, Y658C, and E840K substitutions were not found in controls. All missense mutations led to decreased PDE11A activity in human embryonic kidney 293 and PC3M cells and immunostaining of PCa samples with sequence changes showed decreased PDE11A protein expression. CONCLUSION: Our data suggest that, like in the adrenal cortex and the testicular germ cells, PDE11A-inactivating genetic alterations may play a role in susceptibility to PCa.
CONTEXT: Among the genomic loci harboring potential candidate genes for prostatic cancer (PCa) is the 2q31-33 chromosomal region that harbors the gene encoding phosphodiesterase 11A (PDE11A). In addition, the combined cancer genome expression metaanalysis datasets included PDE11A among the top 1% down-regulated genes in PCa. OBJECTIVE: In the present study, we screened 50 unrelated PCa patients of Brazilian descent for PDE11A coding defects. DESIGN: The study consisted of PDE11A sequencing, in vitro functional assays, and immunostaining analysis. RESULTS: We identified eight different sequence alterations in 15 patients (30%): one stop-codon and seven missense mutations. Three of the variants (R202C, Y658C, and E840K) were novel, and the remaining five (Y727C, R804H, R867G, M878V, and R307X) have been associated with predisposition to adrenal or testicular tumors. The overall prevalence of PDE11A-inactivating sequence variants among PCa patients was significantly higher than in 287 healthy controls (0.16 vs. 0.051, respectively, P < 0.001, odds ratio 3.81, 95% confidence interval 1.86-7.81) and the R202C, Y658C, and E840K substitutions were not found in controls. All missense mutations led to decreased PDE11A activity in humanembryonic kidney 293 and PC3M cells and immunostaining of PCa samples with sequence changes showed decreased PDE11A protein expression. CONCLUSION: Our data suggest that, like in the adrenal cortex and the testicular germ cells, PDE11A-inactivating genetic alterations may play a role in susceptibility to PCa.
Authors: Anelia Horvath; Christoforos Giatzakis; Audrey Robinson-White; Sosipatros Boikos; Elizabeth Levine; Kurt Griffin; Erica Stein; Virginia Kamvissi; Payal Soni; Ioannis Bossis; Wouter de Herder; J Aidan Carney; Jérôme Bertherat; Peter K Gregersen; Elaine F Remmers; Constantine A Stratakis Journal: Cancer Res Date: 2006-12-15 Impact factor: 12.701
Authors: S V Tavtigian; J Simard; D H Teng; V Abtin; M Baumgard; A Beck; N J Camp; A R Carillo; Y Chen; P Dayananth; M Desrochers; M Dumont; J M Farnham; D Frank; C Frye; S Ghaffari; J S Gupte; R Hu; D Iliev; T Janecki; E N Kort; K E Laity; A Leavitt; G Leblanc; J McArthur-Morrison; A Pederson; B Penn; K T Peterson; J E Reid; S Richards; M Schroeder; R Smith; S C Snyder; B Swedlund; J Swensen; A Thomas; M Tranchant; A M Woodland; F Labrie; M H Skolnick; S Neuhausen; J Rommens; L A Cannon-Albright Journal: Nat Genet Date: 2001-02 Impact factor: 38.330
Authors: Charles C Chung; Wagner C S Magalhaes; Jesus Gonzalez-Bosquet; Stephen J Chanock Journal: Carcinogenesis Date: 2009-11-11 Impact factor: 4.944
Authors: Hartmut Porst; Kevin T McVary; Francesco Montorsi; Peter Sutherland; Albert Elion-Mboussa; Anne M Wolka; Lars Viktrup Journal: Eur Urol Date: 2009-04-22 Impact factor: 20.096
Authors: Fabio R Faucz; Anelia D Horvath; Monalisa F Azevedo; Isaac Levy; Beata Bak; Ying Wang; Paraskevi Xekouki; Eva Szarek; Evgenia Gourgari; Allison D Manning; Rodrigo Bertollo de Alexandre; Emmanouil Saloustros; Giampaolo Trivellin; Maya Lodish; Paul Hofman; Yvonne C Anderson; Ian Holdaway; Edward Oldfield; Prashant Chittiboina; Maria Nesterova; Nienke R Biermasz; Jan M Wit; Daniel J Bernard; Constantine A Stratakis Journal: Endocr Relat Cancer Date: 2014-12-19 Impact factor: 5.678
Authors: Rodrigo B de Alexandre; Anelia D Horvath; Eva Szarek; Allison D Manning; Leticia F Leal; Fabio Kardauke; Jonathan A Epstein; Dirce M Carraro; Fernando A Soares; Tatiyana V Apanasovich; Constantine A Stratakis; Fabio R Faucz Journal: Endocr Relat Cancer Date: 2015-05-15 Impact factor: 5.678
Authors: Crystal D C Kamilaris; Fady Hannah-Shmouni; Constantine A Stratakis Journal: Best Pract Res Clin Endocrinol Metab Date: 2020-05-23 Impact factor: 4.690
Authors: Anna Angelousi; Filip Fencl; Fabio R Faucz; Jana Malikova; Zdenek Sumnik; Jan Lebl; Constantine A Stratakis Journal: Hormones (Athens) Date: 2015 Jul-Sep Impact factor: 2.885